Researchers from UVA Health and Virginia Tech have developed a novel SARS-CoV-2 vaccine utilizing an inexpensive and effective platform that holds the potential to tackle most of the COVID-19 variants. Read this article to know about this exciting discovery. The major challenges currently faced in fighting the pandemic are: Reinfection post-vaccination Evolution of new mutants rendering vaccines ineffective High production cost of mRNA vaccines Spoilage of vaccine due to strict temperature storage requirements Researchers have reported a new synthetic biology-based vaccine platform that can produce easily scalable, inexpensive vaccines without strict storage and transport constraints.
Furthermore, using this vaccine platform they have developed a novel evolution-resistant SARS-CoV-2 vaccine which was tested to be effective in the porcine model. How does this platform work? One of the…
